Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-25-020240
Filing Date
2025-05-22
Accepted
2025-05-22 21:00:36
Documents
1
Period of Report
2025-05-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 form4.html 4  
1 FORM 4 form4.xml 4 3195
  Complete submission text file 0001140361-25-020240.txt   4792
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Issuer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ROIVANT SCIENCES, INC. 151 W. 42ND ST., 15TH FLOOR NEW YORK NY 10036
Business Address
Gline Matthew (Reporting) CIK: 0001750094 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40782 | Film No.: 25979002